Amelia Dennis’ Post

📰 New Research Alert! 🌟Dive into the intricate world of ANCA-associated vasculitis with our latest review article on anti-MPO (myeloperoxidase) antibodies. 🔬Uncover the mechanisms, clinical manifestations, and cutting-edge diagnostic strategies for these complex autoimmune conditions. This is about : 🔥 Neutrophil Activation: Neutrophils become both targets and effectors of autoimmunity. 🔄 Immunopathological Response: This activation leads to tissue and organ damage. 🧠 Implications: Understanding these mechanisms is crucial for developing new treatments. This comprehensive review in the Special Issue on ANCA-associated vasculitis is a must-read for researchers, clinicians, and anyone passionate about advancing our understanding of autoimmune diseases. Here are the key points: 🏥 Clinical Impact: Severe impairment of kidney and lung functions. 🔬 Future Research: Focus on immune mechanisms and developing more effective treatments. 🌟 Prospects: New approaches to improve the management of this autoimmune disease. Our article in The Lancet Rheumatology highlights how innovative research will pave the way for new therapies and a better understanding of autoimmunity. A great thanks to Peter Lamprecht for leading this project with Antje Müller, Sabrina Arnold, Sebastian Klapa, Sara Comdühr, and Anja Stähle from University of Lübeck and the co-authors A. Richard Kitching from Monash University, Victoria; Thorsten Wiech from University Hospital Hamburg-Eppendorf; Ulrich Specks from Mayo Clinic College of Medicine and Science, Rochester. Let's continue to explore 🚀 the future of ANCA-associated vasculitis pathophysiology. 👉 Read the full article here The Lancet Rheumatology and discover the details of our review ! #MedicalResearch #Autoimmunity #Innovation #Health #Research #Vasculitis #ANCA #AntiMPO #antiPR3 #AutoimmuneDisease #MedicalResearch #TheLancetRheumatology #Neutrophil #Inflammation

📃Scientific paper: MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression Abstract: International audience; Background: The major risk factor for idiopathic pulmonary fibrosis (IPF), MUC5B rs35705950, was found to be associated with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Whilst the MUC5B rs35705950 T risk allele has been associated with better survival in IPF, its impact on RA-ILD prognosis remains to be determined. Our objective was to explore the influence of MUC5B rs35705950 on survival and progression in RA-ILD. Methods: Through an international retrospective observational study, patients with RA-ILD were genotyped for the MUC5B rs35705950 variant and consecutive pulmonary function tests (PFTs) findings were collected. Longitudinal data up to a 10-year follow-up were considered and analyzed using mixed regression models. Proportional hazards and joint proportional hazards models were used to analyze the association of baseline and longitudinal variables with lung transplant-free survival. Significant progression of RA-ILD was defined as at least an absolute or relative 10% decline of forced vital capacity at 2 years from baseline. Results: Out of 321 registered patients, 261 were included in the study: 139 women (53.3%), median age at RA-ILD diagnosis 65 years (interquartile range [IQR] 57 to 71), 151 ever smokers (59.2%). Median follow-up was 3.5 years (IQR 1.3 to 6.6). Mortality rate was 32% (95%CI 19 to 42) at 10 years. The MUC5B rs35705950 variant did not impact lung transplant-free survival (HR ... Continued on ES/IODE ➡️ https://etcse.fr/dqTu ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Thrilled to announce our partnership with Scipher Medicine! Together we will transform the autoimmune space by combining the powerful clinical data of OMNY Health's national network with the rich genomic insights from PrismRA, a personalized blood test for #rheumatoidarthritis. Looking forward to this seeing this novel precision medicine collaboration fueling the development of more targeted therapies and improving overall patient outcomes for #autoimmune patients.

Identifying and matching patients for clinical trials can be challenging across various #therapeutic areas due to specific issues related to patient characteristics, disease prevalence, and clinical trial design. Here’s a summary of therapies that are critical in finding patients **1. Rare Diseases Prevalence: Rare diseases affect fewer than 200,000 individuals in the U.S. or a similar proportion in other countries. Examples include cystic fibrosis, Duchenne muscular dystrophy, and certain genetic disorders. **2. Oncology Prevalence: Over 1.8 million new cancer cases are expected in the U.S. in 2023, but only a fraction may fit specific trial criteria. **3. Neurology Prevalence: Alzheimer’s disease affects an estimated 6.7 million people in the U.S. age 65 and older. Many are not eligible due to the specific requirements for clinical trials. **4. Immunology and Autoimmune Diseases Prevalence: There are approximately 24 million people with autoimmune diseases in the U.S., but specific trial criteria may limit the number of eligible participants. **5. Cardiology Prevalence: Cardiovascular diseases affect about 697,000 people in the U.S. each year, but only a subset may meet trial criteria. **6. Infectious Diseases Prevalence: Global infectious disease incidence varies widely; for example, over 230 million cases of malaria and over 10 million cases of tuberculosis were reported in recent years. **7. Endocrinology Prevalence: Approximately 37.3 million people in the U.S. have diabetes, but specific trial eligibility criteria may narrow the pool significantly. Summary: In summary, #rare diseases, #oncology, #neurology, #immunology, #cardiology, #infectious diseases, and #endocrinology present significant issues in patient identification and matching for clinical trials

Scipher Medicine and OMNY Health today announced a partnership to advance precision medicine efforts for immunology. This collaboration marks a significant leap forward in the fight against autoimmune diseases, integrating transcriptomic data from Scipher with OMNY Health's vast EHR network that reaches more than 80 million patients. OMNY Health’s network includes data from nearly 250,000 patients with rheumatoid arthritis (RA), which enables comprehensive tracking of patient outcomes and disease progression.   This partnership unlocks a wealth of information for researchers and drug developers. By combining the detailed clinical data within OMNY Health's network with the rich genomic insights from PrismRA, a personalized blood test for RA, researchers may gain a holistic view of the patient journey. This deeper understanding will fuel the development of more targeted therapies and improve overall patient outcomes.   #PrecisionMedicine #AutoimmuneDisease #RheumatoidArthritis #TargetedTherapy #RealWorldEvidence #ArtificialIntelligence https://lnkd.in/e825Xqp4

🔍 Long-Term Study Illuminates Inherited Retinal Diseases 🌟 A decade-long investigation into rod-cone dystrophies (RCDs) has unveiled critical insights into the progression of this inherited retinal disease. Key Findings: - Participant Overview: 23 individuals diagnosed with retinitis pigmentosa were assessed, revealing that 60% experienced a decline in visual acuity over ten years, while 40% showed no significant progression. - Symmetry in Progression: The study found high symmetry in disease progression between eyes, emphasizing the need for diverse outcome measures in clinical trials. - Importance of Genetic Testing: Advancements have enabled precise classification of retinal diseases, paving the way for tailored treatment strategies. This research highlights the complexity of tracking RCDs and underscores that visual acuity alone may not be a reliable indicator. Healthcare professionals can leverage these insights to enhance patient management and improve outcomes. For a deeper dive into this groundbreaking study and its implications for future research, click on the link! 🔗 #ClinicalResearches #GeneticTesting #InheritedDiseases #MedicalResearch #PatientCare #Publications #RegulatoryAgencies #RetinalHealth #MarketAccess #MarketAccessToday

Breakthrough in Fatty Liver Disease: Two Types Identified Researchers from Karolinska Institutet and the University of Gothenburg have identified two distinct types of metabolic-associated fatty liver disease (MASLD): Liver-Specific MASLD – Aggressively damages the liver but offers some protection against cardiovascular diseases. Systemic MASLD – Affects multiple organs, increasing risks of diabetes, heart, and kidney failure. Key Highlights: 27 genetic variants linked to MASLD were identified, enabling risk prediction through simple clinical calculators. Findings allow personalized treatments based on genetic and clinical profiles. MASLD affects 1 in 4 adults worldwide, often undetected until advanced stages. Advances in Treatment and Diagnosis: Precision medicine is now possible with tailored interventions for specific MASLD types. Lifestyle modifications (e.g., Mediterranean diets) and emerging therapies targeting genetic pathways show promise. This research improves diagnosis, predicts disease progression, and emphasizes the importance of early detection and genetic research in combating MASLD.

The G-protein coupled receptor GPR65, expressed primarily in immune cells, is an important regulator of homeostasis, responding to changes in extracellular pH caused by inflammation and tumorigenesis, and has been associated with several autoimmune and inflammatory diseases. One GPR65 variant associated with inflammatory bowel disease leads to decreased receptor signaling, dampening immune activity and heightening inflammation. Ilona Neale, Daniel Graham and Ramnik Xavier identified a molecular probe that binds to GPR65 and spurs receptor signaling at low pH, where GPR65 plays an important role, effectively rebalancing inflammation and immune signaling. Read more in Science Advances. #BroadInstitute #Science #ScienceNews #Research #ScientificResearch

A Recent Study Uncovers Genetic Insights into MASLD and Its Clinical Implications https://lnkd.in/eDNaHzQE Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the accumulation of lipids in the liver, often accompanied by features of metabolic syndrome. It can progress to cirrhosis and liver cancer. While MASLD frequently clusters with cardiometabolic diseases, new research highlights key genetic distinctions that challenge the assumption of a direct causal link between the two. In this study, researchers identified 27 novel genetic loci associated with MASLD through measurements of visceral adiposity in a cohort of over 36,000 individuals, with six loci replicated in four independent cohorts. Using these genetic findings, two distinct polygenic risk scores were developed, revealing the presence of two subtypes of MASLD: ➡️Liver-Confined MASLD: 1️⃣Associated with aggressive liver disease progression. 2️⃣Limited systemic impact and minimal connection to cardiometabolic conditions. ➡️ Systemic MASLD: 1️⃣ Linked to an increased risk of cardiometabolic diseases, such as cardiovascular disease and type 2 diabetes. 2️⃣ Shares features of lipoprotein retention and metabolic dysfunction beyond the liver.  ✴️ Why This Matters: These findings provide critical insights into the heterogeneity of MASLD, offering a deeper understanding of its biological mechanisms and clinical trajectories. By distinguishing between liver-confined and systemic MASLD, clinicians can better predict patient outcomes and develop precision medicine approaches tailored to each subtype. This research paves the way for innovative strategies in diagnosing and managing MASLD, bridging the gap between genetic predisposition and clinical outcomes. #MASLD #GeneticResearch #PrecisionMedicine #LiverDisease #CardiometabolicHealth #HealthcareInnovation

I am pleased to announce the publication of my latest research article in the *Turkish Immunology Journal*! In this study, we explore the intricate relationship between Toll-like receptors (TLRs) and diabetic nephropathy (DN), one of the most prevalent kidney diseases. Despite its commonality, the exact mechanisms underlying DN remain elusive. Our findings highlight the crucial roles of TLR2, TLR4, TLR5, TLR7, TLR8, TLR9, and TLR11 in the pathogenesis of DN, supported by both in vivo and in vitro evidence. Notably, we discovered that TLR2 and TLR4 are significantly upregulated in patients with renal failure and nephrotic diabetes, contributing to podocyte injury and inflammation triggered by high glucose levels. This suggests that targeting TLR2 and TLR4 could offer promising therapeutic strategies to prevent or delay DN in individuals with type 2 diabetes mellitus. Additionally, our research indicates that TLR7 may also play a role in kidney damage associated with type 1 diabetes mellitus, while downregulation of TLR9 appears to inhibit inflammation and apoptosis pathways linked to DN. I invite you to read the full article for a deeper understanding of these important findings and their potential implications for treatment strategies. 🔗 https://lnkd.in/dysnANSm #DiabeticNephropathy #Immunology #Research #TLRs #KidneyDisease #Type2Diabetes #MedicalResearch #TurkishImmunologyJournal